Generate QR code
Open Access
Subscription Access
Prevalence and risk factors of stroke in patients with HIV infection
https://doi.org/10.30629/0023-2149-2025-103-5-333-338
Abstract
Stroke in patients with HIV infection is a significant medical problem associated with a number of specific risk factors and increased prevalence compared to the general population. In recent decades, improvements in antiretroviral therapy have significantly increased the life expectancy of HIV patients, which has led to an increase in chronic diseases, including cardiovascular and cerebrovascular. The prevalence of stroke in HIV patients is significantly higher, which is due to the multifactorial nature of stroke, including both HIVspecific mechanisms and traditional risk factors. Risk factors for stroke in HIV patients include age, duration of infection, high viral load, low CD4 cell count, the presence of concomitant diseases such as hypertension and diabetes mellitus, and smoking. In addition, certain types of antiretroviral therapy may increase the risk. To reduce the risk of stroke in HIV patients, a comprehensive approach is needed, including control of viral load, regular monitoring of cardiovascular health, lifestyle changes and correction of risk factors such as hypertension, hyperlipidemia and diabetes. Objective: to review the current literature on the problem of stroke in HIV infection in terms of prevalence and risk factors.
About the Authors
F. A. Yusupov
Osh State University
Kyrgyzstan
Kyrgyzstan
Furkat A.Yusupov – Doctor of Medical Sciences, Professor of the Faculty of Medicine
Osh
I. T. Ydyrysov
Osh State University
Kyrgyzstan
Kyrgyzstan
Ismatilla T. Ydyrysov – Doctor of Medical Sciences, Professor of the Faculty of Medicine
Osh
A. A. Yuldashev
Osh State University
Kyrgyzstan
Kyrgyzstan
Akmal A. Yuldashev – postgraduate student of the Department of Neurology, Neurosurgery and Psychiatry of the Medical Faculty
Osh
References
1. Cardiovascular risk in HIV-infected patients. Rev. Port. Cardiol. (Engl. Ed.). 2019; 38 (English, Portuguese. Epub 2019 Sep 13. PMID: 31526559. 2019;38(7):471–472. DOI: 10.1016/j.repc.2019.08.007
2. Smith B. Toward Understanding the When and Why of Human Immunodeficiency Virus-Associated Stroke. J. Infect. Dis. 2017;216(5):509–510. DOI: 10.1093/infdis/jix343
3. Du M., Wang Y., Qin C., Mi D., Liu M., Liu J. Prevalence and incidence of stroke among people with HIV. AIDS. 2023;37(11):1747–1756. DOI: 10.1097/QAD.0000000000003632. Epub 2023 Jun 21. Erratum in: AIDS. 2024;38(5):777. DOI: 10.1097/01.aids.0001010036.38801.fb. PMID: 37352496; PMCID: PMC10399939.
4. Teeraananchai S., Kerr S.J., Amin J., Ruxrungtham K., Law M.G. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256–266. DOI: 10.1111/hiv.12421. Epub 2016 Aug 31. PMID: 27578404.
5. Feinstein M.J., Hsue P.Y., Benjamin L.A., Bloomfield G.S., Currier J.S., Freiberg M.S., Grinspoon S.K., Levin J., Longenecker C.T., Post W.S. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019;140(2):e98–e124. DOI: 10.1161/CIR.0000000000000695. Epub 2019 Jun 3. PMID: 31154814; PMCID: PMC7993364.
6. Ismael S., Moshahid Khan M., Kumar P., Kodidela S., Mirzahosseini G., Kumar S., Ishrat T. HIV Associated Risk Factors for Ischemic Stroke and Future Perspectives. Int. J. Mol. Sci. 2020;21(15):5306. DOI: 10.3390/ijms21155306. PMID: 32722629; PMCID: PMC7432359.
7. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin. Infect. Dis. 2010;50(10):1387–1396. DOI: 10.1086/652283.
8. Ovbiagele B., Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76(5):444–450. DOI: 10.1212/WNL.0b013e31820a0cfc.
9. Yen YF., Chen M., Jen I. et al. Association of HIV and Opportunistic Infections With Incident Stroke: A Nationwide Population-Based Cohort Study in Taiwan. J. Acquir. Immune Defic. Syndr. 2017;74(2):117–125. DOI: 10.1097/QAI.0000000000001216.
10. Hanna D.B., Post W.S., Deal J.A. et al. HIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis. Clin. Infect. Dis. 2015;61(4):640–650. DOI: 10.1093/cid/civ325.
11. Cruse B, Cysique LA, Markus R, Brew BJ. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J. Neurovirol. 2012;18(4):264–76. DOI: 10.1007/s13365-012-0092-3. Epub 2012 Apr 14. PMID: 22528476.
12. Chetty R., Batitang S., Nair R. Large artery vasculopathy in HIV-positive patients: another vasculitic enigma. Hum. Pathol. 2000;31(3):374–9. DOI: 10.1016/s0046-8177(00)80253-1. PMID: 10746682.
13. Kuller LH., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. DOI: 10.1371/journal.pmed.0050203.
14. Abdurakhmanov A., Zandman-Goddard G. HIV Spectrum and autoimmune diseases. In: Shoenfeld Y., Agmon-Levin N., Rose N.R., editors. Infection and Autoimmunity. Academic Press. 2015:371–92.
15. Ntusi NB., Taylor D., Naidoo NG., Mendelson M. Progressive human immunodeficiency virus-associated vasculopathy: time to revise antiretroviral therapy guidelines? Cardiovasc. J. Afr. 2011;22(4):197–200. DOI: 10.5830/CVJA-2010-048. PMID: 21881685.
16. Anderson A.M., Fountain J.A., Green S.B., Bloom S.A., Palmore M.P. Human immunodeficiency virus-associated cytomegalovirus infection with multiple small vessel cerebral infarcts in the setting of early immune reconstitution. J. Neurovirol. 2010;16(2):179–84. DOI: 10.3109/13550281003735717. PMID: 20370600.
17. Zhang X., Li H., Li T., Zhang F., Han Y. Distinctive rheumatic manifestations in 98 patients with human immunodeficiency virus infection in China. J Rheumatol. 2007Aug;34(8):1760–4. Epub 2007 Jul 15. PMID: 17659750.
18. Benjamin LA., Bryer A., Emsley HC., Khoo S., Solomon T., Connor M.D. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11(10):878–890. DOI: 10.1016/S1474-4422(12)70205-3.
19. Rosario M., Song SX., McCullough LD. An unusual case of stroke. Neurologist. 2012;18(4):229–232. DOI: 10.1097/NRL.0b013e31825bbf4d.
20. Kieburtz K.D., Eskin T.A., Ketonen L., Tuite M.J. Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. Arch. Neurol. 1993;50(4):430–2. DOI: 10.1001/archneur.1993.00540040082019. PMID: 8460966.
21. Daramola O., Ali H., Mckenzie C.A., Smith C., Benjamin L.A., Solomon T. Pre-clinical atherosclerosis is found at post-mortem, in the brains of men with HIV. J. Neurovirol. 2021;27(1):80–85. DOI: 10.1007/s13365-020-00917-1.
22. Benjamin LA., Allain TJ., Mzinganjira H., et al. The Role of Human Immunodeficiency Virus-Associated Vasculopathy in the Etiology of Stroke. J. Infect. Dis. 2017;216(5):545–553. DOI: 10.1093/infdis/jix340.
23. Corbett C., Brey N., Pitcher R.D., O’Hagan S., Esterhuizen T.M., Chow F.C., Decloedt E.H. Prevalence and Characteristics of HIV-Associated Stroke in a Tertiary Hospital Setting in South Africa. Neurology. 2022;99(9):e904–e915. DOI: 10.1212/WNL.0000000000200780. Epub 2022 Jun 3. PMID: 36038281; PMCID: PMC9502736.
24. Venter W.D.F., Moorhouse M., Sokhela S., Fairlie L., Mashabane N., Masenya M., Serenata C., Akpomiemie G., Qavi A., Chandiwana N., Norris S., Chersich M., Clayden P., Abrams E., Arulappan N., Vos A., McCann K., Simmons B., Hill A. Долутегравир плюс два разных пролекарства Тенофовира для лечения ВИЧ-инфекции. Тенофовир для лечения ВИЧ. На английском. J. Med. 2019;381(9):803–815. DOI: 10.1056/NEJMoa1902824. Epub 2019, 24 июля. PMID: 31339677.
25. Chow F.C., Boscardin W.J., Mills C. et al. Cerebral vasoreactivity is impaired in treated, virally suppressed HIV-infected individuals. AIDS. 2016;30(1):45–55. DOI: 10.1097/QAD.0000000000000875.
26. Chow F.C., Wilson M.R., Wu K., Ellis R.J., Bosch R.J., Linas B.P. Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal LinkedRandomized Trials cohort. AIDS. 2018;32(9):1125–1135. DOI: 10.1097/QAD.0000000000001799.
27. Chow F.C., Regan S., Zanni MV. et al. Elevated ischemic stroke risk among women living with HIV infection. AIDS. 2018;32(1):59–67. DOI: 10.1097/QAD.0000000000001650.
28. Gutierrez J., Menshawy K., Gonzalez M. et al. Brain large artery inflammation associated with HIV and large artery remodeling. AIDS. 2016;30(3):415–423. DOI: 10.1097/QAD.0000000000000927.
29. Vishnu P., Aboulafia D.M. Haematological manifestations of human immune deficiency virus infection. Br. J. Haematol. 2015;171(5):695–709. DOI: 10.1111/bjh.13783. Epub 2015 Oct 9. PMID: 26452169.
30. Ortiz G., Koch S., Romano J.G., Forteza A.M., Rabinstein A.A. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007;68(16):1257–61. DOI: 10.1212/01.wnl.0000259515.45579.1e. PMID: 17438215.
31. Stahl C.P., Wideman C.S., Spira T.J., Haff E.C., Hixon G.J., Evatt B.L. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993;81(7):1801–7. PMID: 8461466.
32. Giannakopoulos B., Passam F., Ioannou Y., Krilis S.A. How we diagnose the antiphospholipid syndrome. Blood. 2009Jan29;113(5):985–94. DOI: 10.1182/blood-2007-12-129627. Epub 2008 Aug 28. PMID: 18755986.
33. Haugaard A.K., Lund T.T., Birch C., Rönsholt F., Trøseid M., Ullum H., Gerstoft J., Johansson P.I., Nielsen S.D., Ostrowski S.R. Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation. AIDS. 2013;27(17):2749–58. DOI: 10.1097/01.aids.0000432462.21723.ed. PMID: 23842126.
34. Singer E.J., Valdes-Sueiras M., Commins D.L., Yong W., Carlson M. HIV stroke risk: evidence and implications. Ther. Adv. Chronic. Dis. 2013;4(2):61–70. DOI: 10.1177/2040622312471840.
35. Lorenz M.W., Stephan C., Harmjanz A., Staszewski S., Buehler A., Bickel M., von Kegler S., Ruhkamp D., Steinmetz H., Sitzer M. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196(2):720–6. DOI: 10.1016/j.atherosclerosis.2006.12.022. Epub 2007 Feb 1. PMID: 17275008.
36. Seaberg E.C., Benning L., Sharrett A.R. et al. Association between human immunodeficiency virus infection and stiffness of the common carotid artery. Stroke. 2010;41(10):2163–2170. DOI: 10.1161/STROKEAHA.110.583856.
37. Oliviero U., Bonadies G., Apuzzi V., Foggia M., Bosso G., Nappa S., Valvano A., Leonardi E., Borgia G., Castello G., Napoli R., Saccà L. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis. 2009;204(2):586–9. DOI: 10.1016/j.atherosclerosis.2008.10.012. Epub 2008 Nov 1. PMID: 19084229.
38. Neuhaus J., Jacobs DR Jr., Baker J.V. et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J. Infect. Dis. 2010;201(12):1788–1795. DOI: 10.1086/652749.
39. Libby P., Ridker P.M., Hansson G.K. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 2009;54(23):2129–2138. DOI: 10.1016/j.jacc.2009.09.009.
40. Chi D., Henry J., Kelley J., Thorpe R., Smith JK., Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium. 2000;7(4):223–42. DOI: 10.3109/10623320009072210. PMID: 11201521.
41. Eugenin EA., Morgello S., Klotman ME. et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIVmediated vascular disease. Am. J. Pathol. 2008;172(4):1100–1111. DOI: 10.2353/ajpath.2008.070457.
42. Kline E.R., Sutliff R.L. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J. Investig. Med. 2008;56(5):752–769. DOI: 10.1097/JIM.0b013e3181788d15.
43. Fisher S.D., Miller T.L., Lipshultz S.E. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006;185(1):1–11. DOI: 10.1016/j.atherosclerosis.2005.09.025. Epub 2005 Nov 16. PMID: 16297390.
44. Buonaguro L., Barillari G., Chang HK., et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 1992;66(12):7159–7167. DOI: 10.1128/JVI.66.12.7159-7167.1992.
45. Scala G., Ruocco MR., Ambrosino C. et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J. Exp. Med. 1994;179(3):961–971. DOI: 10.1084/jem.179.3.961
46. Rieckmann P., Poli G., Fox C.H., Kehrl J.H., Fauci A.S. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol. 1991;147(9):2922–7. PMID: 1918999.
47. Lee C., Liu QH., Tomkowicz B., Yi Y. Freedman BD., Collman RG. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J Leukoc Biol. 2003Nov;74(5):676–82. DOI: 10.1189/jlb.0503206. Epub 2003 Jul 22. PMID: 12960231.
48. Swingler S., Mann A., Jacqué J. et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat. Med. 1999;5(9):997–103. DOI: 10.1038/12433.
49. Hsue P Hunt P Schnell A et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–1067. DOI: 10.1097/QAD.0b013e32832b514b.
50. Guedes B.F., Gomes H.R., Lucato L.T., Puglia P.Jr., Nitrini R., Castro L.H. Human immunodeficiency virus-associated vasculopathy with CNS compartmentalization of HIV-1. J. Neurovirol. 2015;21(1): 101–4. DOI: 10.1007/s13365-014-0307-x. Epub 2014 Dec 24. PMID: 25537635.
51. Ake J.A., Erickson J.C., Lowry K.J. Cerebral aneurysmal arteriopathy associated with HIV infection in an adult. Clin. Infect. Dis. 2006;43(5):e46–50. DOI: 10.1086/506566. Epub 2006 Jul 26. PMID: 16886142.
52. Kossorotoff M., Touzé E., Godon-Hardy S., Serre I., Mateus C., Mas J.L., Zuber M. Cerebral vasculopathy with aneurysm formation in HIV-infected young adults. Neurology. 2006;66(7):1121–2. DOI: 10.1212/01.wnl.0000204188.85402.0c. PMID: 16606935.
53. Maher D., Harries A., Getahun H. Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies. Trop. Med. Int. Health. 2005;10(8):734–42. DOI: 10.1111/j.1365-3156.2005.01456.x. PMID: 16045459.
54. Lammie G.A., Hewlett R.H., Schoeman J.F., Donald P.R. Tuberculous cerebrovascular disease: a review. J. Infect. 2009;59(3):156–66. DOI: 10.1016/j.jinf.2009.07.012. Epub 2009 Jul 25. PMID: 19635500.
55. Gutierrez J., Ortiz G. HIV/AIDS patients with HIV vasculopathy and VZV vasculitis: a case series. Clin. Neuroradiol. 2011;21(3):145–51. DOI: 10.1007/s00062-011-0087-0. Epub 2011 Jul 20. PMID: 21773670.
56. Chahine L.M., Khoriaty R.N., Tomford W.J., Hussain M.S. The changing face of neurosyphilis. Int. J. Stroke. 2011;6(2):136–43. DOI: 10.1111/j.1747-4949.2010.00568.x. Epub 2011 Jan 10. PMID: 21371276.
57. Garg R.K., Sinha M.K. Tuberculous meningitis in patients infected with human immunodeficiency virus. J. Neurol. 2011;258(1):3–13. DOI: 10.1007/s00415-010-5744-8. Epub 2010 Sep 17. PMID: 20848123.
58. Sanders J.M., Steverson A.B., Pawlowski A.E. et al. Atrial arrhythmia prevalence and characteristics for human immunodeficiency virusinfected persons and matched uninfected controls. PLoS One. 2018;13(3):e0194754. Published 2018 Mar 20. DOI: 10.1371/journal.pone.0194754.
59. Pugliese A., Isnardi D., Saini A., Scarabelli T., Raddino R., Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J. Infect. 2000;40(3):282–4. DOI: 10.1053/jinf.2000.0672. PMID: 10908024.
60. Barbaro G., Fisher S.D., Lipshultz S.E. Pathogenesis of HIVassociated cardiovascular complications. Lancet Infect Dis. 2001;1(2):115–24. DOI: 10.1016/S1473-3099(01)00067-6. Erratum in: Lancet Infect. Dis. 2004;4(8):533. PMID: 11871462.
61. Magula N.P., Mayosi B.M. Cardiac involvement in HIVinfected people living in Africa: a review. Cardiovasc. J. S. Afr. 2003;14(5):231–7. PMID: 14610610.
62. Ntsekhe M., Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat. Clin. Pract. Cardiovasc. Med. 2009;6(2):120–7. DOI: 10.1038/ncpcardio1437. Epub 2008 Dec 23. PMID: 19104517.
63. Bogorodskaya M., Chow F.C., Triant V.A. Stroke in HIV. Can. J. Cardiol. 2019;35(3):280–287. DOI: 10.1016/j.cjca.2018.11.032.
64. d’Arminio A., Sabin C.A., Phillips A.N., Reiss P., Weber R., Kirk O., El-Sadr W., De Wit S., Mateu S., Petoumenos K., Dabis F., Pradier C., Morfeldt L., Lundgren J.D., Friis-Møller N. Writing Committee of the D:A:D: Study Group. Cardioand cerebrovascular events in HIV-infected persons. AIDS.2004;18(13):1811–7. DOI: 10.1097/00002030-200409030-00010. PMID: 15316342.
65. Chow F.C., Bacchetti P., Kim A.S., Price R.W., Hsue P.Y. Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection. AIDS. 2014;28(17):2573–2577. DOI: 10.1097/QAD.0000000000000452.
66. Sabin C.A., Ryom L., De Wit S., Mocroft A., Phillips A.N., Worm S.W., Weber R., D’Arminio Monforte A., Reiss P., Kamara D., El-Sadr W., Pradier C., Dabis F., Law M., Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013;27(17):2735–48. DOI: 10.1097/01.aids.0000432457.91228.f3. PMID: 23842128.
67. Emsley H.C., Tyrrell P.J. Inflammation and infection in clinical stroke. J. Cereb. Blood Flow Metab. 2002;22(12):1399–419. DOI: 10.1097/01.WCB.0000037880.62590.28. PMID: 12468886.
68. Solages A., Vita J.A., Thornton D.J. et al. Endothelial function in HIV-infected persons. Clin. Infect. Dis. 2006;42(9):1325–1332. DOI: 10.1086/503261.
69. Ross A.C., Rizk N., O’Riordan M.A. et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin. Infect. Dis. 2009;49(7):1119–1127. DOI: 10.1086/605578.
70. Ryom L., Lundgren J.D., El-Sadr W., Reiss P., Kirk O., Law M., Phillips A., Weber R., Fontas E., d’Arminio Monforte A., De Wit S., Dabis F., Hatleberg C.I., Sabin C., Mocroft A. D:A:D study group. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018;5(6):e291–e300. DOI: 10.1016/S2352-3018(18)30043-2. Epub 2018 May 3. PMID: 29731407.
71. Stein J.H., Ribaudo H.J., Hodis H.N. et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness [published correction appears in AIDS. 2016;30(2):337]. AIDS. 2015;29(14):1775–1783. DOI: 10.1097/QAD.0000000000000762.
72. Bavinger C., Bendavid E., Niehaus K. et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One. 2013;8(3):e59551. DOI: 10.1371/journal.pone.0059551.
73. Bertrand L., Velichkovska M., Toborek M. Cerebral Vascular Toxicity of Antiretroviral Therapy. J. Neuroimmune Pharmacol. 2021;16(1):74–89. DOI: 10.1007/s11481-019-09858-x.
74. Abdallah A., Chang J.L., O’Carroll C.B. et al. Stroke in Human Immunodeficiency Virus-infected Individuals in Sub-Saharan Africa (SSA): A Systematic Review. J. Stroke Cerebrovasc. Dis. 2018;27(7):1828–1836. DOI:10.1016/j.jstrokecerebrovasdis.2018.02.016.
75. Benjamin L.A., Corbett E.L., Connor M.D. et al. HIV, antiretroviral treatment, hypertension, and stroke in Malawian adults: A case-control study. Neurology. 2016;86(4):324–333. DOI: 10.1212/WNL.0000000000002278.
76. Qureshi A.I. HIV infection and stroke: if not protein S deficiency then what explains the relationship? J. Neurol. Neurosurg. Psychiatry. 2005;76(10):1331. DOI: 10.1136/jnnp.2005.072017.
77. Mochan A., Modi M., Modi G. Stroke in black South African HIV-positive patients: a prospective analysis. Stroke. 2003;34(1):10–5. DOI: 10.1161/01.str.0000043821.35051.fa. PMID: 12511743.
78. Goff D.C. Jr., Lloyd-Jones D.M., Bennett G., Coady S., D’Agostino R.B., Gibbons R., Greenland P., Lackland D.T., Levy D., O’Donnell C.J., Robinson J.G., Schwartz J.S., Shero S.T., Smith S.C. Jr., Sorlie P., Stone N.J., Wilson P.W., Jordan H.S., Nevo L., Wnek J., Anderson J.L., Halperin J.L., Albert N.M., Bozkurt B., Brindis R.G., Curtis L.H., DeMets D., Hochman J.S., Kovacs R.J., Ohman E.M., Pressler S.J., Sellke F.W., Shen W.K., Smith S.C. Jr., Tomaselli G.F. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25Suppl2):S49–73. DOI: 10.1161/01.cir.0000437741.48606.98. Epub 2013 Nov 12. Erratum in: Circulation. 2014;129(25 Suppl 2):S74–5. PMID: 24222018.
79. Philip Branigan,Y. V Duong,Ammar Y Abdulfattah,Jacob Sabu,Mary Mallappallil,Sabu John,Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies. Cureus. (2024). DOI: 10.7759/cureus.60877.
80. Mdodo R. et al. Cigarette smoking among HIV+ adults in care: Medical Monitoring Project, US, 2009. 20th Conference on Retroviruses and Opportunistic Infections. 2013:3–6.
81. Freiberg M.S., McGinnis K.A., Kraemer K. et al. The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. J. Acquir. Immune Defic. Syndr. 2010;53(2):247–253. DOI: 10.1097/QAI.0b013e3181c6c4b7.
82. Blashill A.J., Mayer K.H., Crane H. et al. Physical activity and health outcomes among HIV-infected men who have sex with men: a longitudinal mediational analysis. Ann. Behav. Med. 2013;46(2):149–156. DOI: 10.1007/s12160-013-9489-3.
83. d’Ettorre G., Ceccarelli G., Giustini N., Mastroianni C.M., Silvestri G., Vullo V. Taming HIV-related inflammation with physical activity: a matter of timing. AIDS Res. Hum. Retroviruses. 2014;30(10):936–944. DOI: 10.1089/AID.2014.0069.
84. Jaggers J.R., Prasad V.K., Dudgeon W.D. et al. Associations between physical activity and sedentary time on components of metabolic syndrome among adults with HIV. AIDS Care. 2014;26(11):1387–1392. DOI: 10.1080/09540121.2014.920075.
85. Hama S., Yamashita H., Shigenobu M., Watanabe A., Hiramoto K., Kurisu K., Yamawaki S., Kitaoka T. Depression or apathy and functional recovery after stroke. Int. J. Geriatr. Psychiatry. 2007;22(10):1046–51. DOI: 10.1002/gps.1866. PMID: 17702056.
Review
For citations:
Yusupov F.A., Ydyrysov I.T., Yuldashev A.A. Prevalence and risk factors of stroke in patients with HIV infection. Clinical Medicine (Russian Journal). 2025;103(5):333-338. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-5-333-338
Views:
12
Email this article 